Mark Gudesblatt, MD

22. Lebwohl M, Tyring SK, Hamilton TK, et al.A novel targeted T-cell modulator, efalizumab,for plaque psoriasis. N Engl J Med.2003;349(1):2004-2013.23. Carson KR, Evens AM, Richey EA, et al.Progressive multifocal leukoencephalopathyafter rituximab therapy in HIVnegativepatients: a report of 57 casesfrom the Research on Adverse DrugEvents and Reports project. Blood.2009;113(20):4834-4840.24. Brew BJ, Davies NW, Cinque P, et al. Progressivemultifocal leukoencephalopathyand other forms of JC virus disease.Nat Rev Neurol. 2010;6(12):667-679.25. Marzocchetti A, Di Giambenedetto S,Cingolani A, et al. Reduced rate of diagnosticpositive detection of JC VirusDNA in cerebrospinal fluid in cases ofsuspected progressive multifocal leukoencephalopathyin the era of potentantiretroviral therapy. J Clin Microbiol.2005;43(8):4175-4177.26. Engsig FN, Hansen AB, Omland LH, et al.Incidence, clinical presentation, and outcomeof progressive multifocal leukoencephalopathyin HIV-infected patientsduring the highly active antiretroviraltherapy era: a nationwide cohort study.J Infect Dis. 2009;199(1):77-83.27. Bossolasco S, Calori G, Moretti F, et al.Prognostic significance of JC virus DNAlevels in cerebrospinal fluid of patientswith HIV-associated progressive multifocalleukoencephalopathy. Clin Infect Dis.2005;40(5):738-744.28. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications forPML risk stratification. Ann Neurol.2010;68(3):295-303.29. Goelz SE, Gorelik L, Subramanyam M.Assay design and sample collectioncan affect anti-John Cummingham virusantibody detection. Ann Neurol.2011;69(2):429-430.30. De Luca A, Giancola ML, Ammassari A,et al. The effect of potent antiretroviraltherapy and JC virus load in cerebrospinalfluid on clinical outcome of patientswith AIDS-associated progressive multifocalleukoencephalopathy. J Infect Dis.2000;182(4):1077-1083.31. Antinori A, Cingolani A, Lorenzini P, etal. Clinical epidemiology and survival ofprogressive multifocal leukoencephalopathyin the era of highly active antiretroviraltherapy: data from the ItalianRegistry Investigative Neuro AIDS (IRI-NA). J Neurovirol. 2003;9(Suppl 1):47-53.32. Berenguer J, Miralles P, Arrizabalaga J,et al. Clinical course and prognostic factorsof progressive multifocal leukoencephalopathyin patients treated withhighly active antiretroviral therapy. ClinInfect Dis. 2003;36(8):1047-1052.33. Wyen C, Hoffmann C, Schmeisser N, etal. Progressive multifocal leukencephalopathyin patients on highly activeantiretroviral therapy: survival and riskfactors of death. J Acquir Immune DeficSyndr. 2004;37(2):1263-1268.34. Falcó V, Olmo M, del Saz SV, et al. Influenceof HAART on the clinical course ofHIV-1-infected patients with progressivemultifocal leukoencephalopathy:results of an observational multicenterstudy. J Acquir Immune Defic Syndr.2008;49(1):26-31.35. Marzocchetti A, Tompkins T, Clifford DB,et al. Determinants of survival in progressivemultifocal leukoencephalopathy.Neurology. 2009;73(19):1551-1558.36. Berger JR, Levy RM, Flomenhoft D,Dobbs M. Predictive factors for prolongedsurvival in acquired immunodeficiencysyndrome-associated progressivemultifocal leukoencephalopathy.Ann Neurol. 1998;44(3):341-349.37. Thurnher MM, Post MJ, Rieger A, et al.Initial and follow-up MR imaging findingsin AIDS-related progressive multifocalleukoencephalopathy treatedwith highly active antiretroviral therapy.AJNR Am J Neuroradiol. 2001;22(5):977-984.38. Taoufik Y, Gasnault J, Karaterki A, et al.Prognostic value of JC virus load in cerebrospinalfluid of patients with progressivemultifocal leukoencephalopathy. JInfect Dis. 1998;178(6):1816-1820.39. Yiannoutsos CT, Major EO, Curfman B,et al. Relation of JC virus DNA in the cerebrospinalfluid to survival in acquiredimmunodeficiency syndrome patientswith biopsy-proven progressive multifocalleukoencephalopathy. Ann Neurol.1999;45(6):816-821.40. Garcia De Viedma D, Diaz Infantes M,Miralles P, et al. JC virus load in progressivemultifocal leukoencephalopathy:analysis of the correlation betweenthe viral burden in cerebrospinal fluid,patient survival, and the volume ofneurological lesions. Clin Infect Dis.2002;34(12):1568-1575.41. Berger JR, Pall L, Lanska D, Whiteman M.Progressive multifocal leukoencephalopathyin patients with HIV infection. JNeurovirol. 1998;4(1):59-68.42. Van Assche G, Van Ranst M, Sciot R,et al. Progressive multifocal leukoencephalopathyafter natalizumab therapyfor Crohn’s disease. N Engl J Med.2005;353(4):362-368.43. Kleinschmidt-DeMasters BK, Tyler KL.Progressive multifocal leukoencephalopathycomplicating treatment withnatalizumab and interferon beta-1afor multiple sclerosis. N Engl J Med.2005;353(4):369-374.44. Langer-Gould A, Atlas SW, Green AJ, etal. Progressive multifocal leukoencephalopathyin a patient treated with natalizumab.N Engl J Med. 2005;353(4):375-381.Clinical Reviews of JCV and PML • July 2011 S27